New Oxadiazole and Pyrazoline Derivatives As Anti-proliferative Agents Targeting EGFR-TK: Design, Synthesis, Biological Evaluation and Molecular Docking Study

Overview

Journal Sci Rep

Specialty Science

Date 2024 Mar 5

PMID 38443456

Authors

Marwa I Serag

Samar S Tawfik

Sahar M I Badr

Hassan M Eisa

Affiliations

Soon will be listed here.

Abstract

Two new series of oxadiazole and pyrazoline derivatives were designed and synthesized as promising EGFR-TK inhibitors. The in vitro antiproliferative activity was studied against three human cancer cell lines; HCT116, HepG-2 and MCF7 using MTT assay. Compound 10c showed the most potent anticancer activity against all cancer cell lines, with IC range of 1.82 to 5.55 μM, while proving safe towards normal cells WI-38 (IC = 41.17 μM) compared to the reference drug doxorubicin (IC = 6.72 μM). The most active candidates 5a, 9b, 10a, 10b and 10c were further assessed for their EGFR-TK inhibition. The best of which, compounds 5a and 10b showed IC of 0.09 and 0.16 μM respectively compared to gefitinib (IC = 0.04 μM). Further investigation against other EGFR family members, showed that 5a displayed good activities against HER3 and HER4 with IC values 0.18 and 0.37 µM, respectively compared to gefitinib (IC = 0.35 and 0.58 µM, respectively). Furthermore, 5a was evaluated for cell cycle distribution and apoptotic induction on HepG-2 cells. It induced mitochondrial apoptotic pathway and increased accumulation of ROS. Molecular docking study came in agreement with the biological results. Compounds 5a and 10b showed promising drug-likeness with good physicochemical properties.

Citing Articles

Exploring pyrazolines as potential inhibitors of NSP3-macrodomain of SARS-CoV-2: synthesis and in silico analysis.

Joshi R, Gaikwad H, Soge B, Alshammari A, Albekairi N, Kabra A Sci Rep. 2025; 15(1):767.

PMID: 39755743 PMC: 11700119. DOI: 10.1038/s41598-024-81711-5.

References

Othman D, Hamdi A, Tawfik S, Elgazar A, Mostafa A . Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition, and studies. J Enzyme Inhib Med Chem. 2023; 38(1):2166037. PMC: 9858449. DOI: 10.1080/14756366.2023.2166037. View

Huang X, Cheng K, Liu L, Hu X, Gao X, Li H . Design, synthesis and apoptosis-related antiproliferative activities of chelidonine derivatives. Bioorg Med Chem Lett. 2019; 30(4):126913. DOI: 10.1016/j.bmcl.2019.126913. View

Nawareg N, Mostafa A, El-Messery S, Nasr M . New benzimidazole based hybrids: Synthesis, molecular modeling study and anticancer evaluation as TopoII inhibitors. Bioorg Chem. 2022; 127:106038. DOI: 10.1016/j.bioorg.2022.106038. View

Nimbalkar U, Tupe S, Vazquez J, Kalam Khan F, Sangshetti J, Nikalje A . Ultrasound- and Molecular Sieves-Assisted Synthesis, Molecular Docking and Antifungal Evaluation of 5-(4-(Benzyloxy)-substituted phenyl)-3-((phenylamino)methyl)-1,3,4-oxadiazole-2(3H)-thiones. Molecules. 2016; 21(5). PMC: 6273549. DOI: 10.3390/molecules21050484. View

Zhang L, Liu Z, Zhang H, Sun J, Luo Y, Zhao T . Synthesis, biological evaluation and molecular docking studies of novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone derivatives. Bioorg Med Chem. 2012; 20(11):3615-21. DOI: 10.1016/j.bmc.2012.03.061. View

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C . Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361(10):958-67. DOI: 10.1056/NEJMoa0904554. View

Kim M, Baek M, Kim D . Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis. Curr Pharm Des. 2017; 23(29):4226-4246. PMC: 6745708. DOI: 10.2174/1381612823666170616082125. View

Halim P, Hassan R, Mohamed K, Hassanin S, Khalil M, Abdou A . Synthesis and biological evaluation of halogenated phenoxychalcones and their corresponding pyrazolines as cytotoxic agents in human breast cancer. J Enzyme Inhib Med Chem. 2021; 37(1):189-201. PMC: 8667918. DOI: 10.1080/14756366.2021.1998023. View

Liu K, Lu X, Zhang H, Sun J, Zhu H . Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents. Eur J Med Chem. 2011; 47(1):473-8. DOI: 10.1016/j.ejmech.2011.11.015. View

10.

Zheng X, Li C, Cui M, Song Z, Bai X, Liang C . Synthesis, biological evaluation of benzothiazole derivatives bearing a 1,3,4-oxadiazole moiety as potential anti-oxidant and anti-inflammatory agents. Bioorg Med Chem Lett. 2020; 30(13):127237. DOI: 10.1016/j.bmcl.2020.127237. View

11.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

12.

Sivakumar S, Reddy M, Cowley A, Vasudevan K . Synthesis and crystal structures of lanthanide 4-benzyloxy benzoates: influence of electron-withdrawing and electron-donating groups on luminescent properties. Dalton Trans. 2010; 39(3):776-86. DOI: 10.1039/b917256d. View

13.

Karabacak M, Altintop M, Ciftci H, Koga R, Otsuka M, Fujita M . Synthesis and Evaluation of New Pyrazoline Derivatives as Potential Anticancer Agents. Molecules. 2015; 20(10):19066-84. PMC: 6332424. DOI: 10.3390/molecules201019066. View

14.

Zeidan M, Mostafa A, Gomaa R, Abou-Zeid L, El-Mesery M, El-Sayed M . Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. Eur J Med Chem. 2019; 168:315-329. DOI: 10.1016/j.ejmech.2019.02.050. View

15.

Warren C, Wong-Brown M, Bowden N . BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 2019; 10(3):177. PMC: 6384907. DOI: 10.1038/s41419-019-1407-6. View

16.

Wassel M, Ammar Y, Elhag Ali G, Belal A, Mehany A, Ragab A . Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. Bioorg Chem. 2021; 110:104794. DOI: 10.1016/j.bioorg.2021.104794. View

17.

Nicoletti I, Migliorati G, Pagliacci M, Grignani F, Riccardi C . A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991; 139(2):271-9. DOI: 10.1016/0022-1759(91)90198-o. View

18.

Yosaatmadja Y, Silva S, Dickson J, Patterson A, Smaill J, Flanagan J . Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. J Struct Biol. 2015; 192(3):539-544. DOI: 10.1016/j.jsb.2015.10.018. View

19.

Farooqi S, Arshad N, Ali Channar P, Perveen F, Saeed A, Larik F . Synthesis, theoretical, spectroscopic and electrochemical DNA binding investigations of 1, 3, 4-thiadiazole derivatives of ibuprofen and ciprofloxacin: Cancer cell line studies. J Photochem Photobiol B. 2018; 189:104-118. DOI: 10.1016/j.jphotobiol.2018.10.006. View

20.

Nawaz F, Alam O, Perwez A, Rizvi M, Naim M, Siddiqui N . 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies. Arch Pharm (Weinheim). 2020; 353(4):e1900262. DOI: 10.1002/ardp.201900262. View